It is difficult to create a suitable formulation for atorvastatin calcium because of its limited solubility and bioavailability. Using Poloxamer 188 as a hydrophilic carrier, a solid dispersion of atorvastatin calcium was produced using the solvent evaporation technique. Afterwards, powder X-ray diffraction, differential scanning calorimetry, scanning electron microscopy, and fourier transform infrared spectroscopy were used to describe this formulation. Furthermore, every one of these investigations proposed the calcium conversion of crystalline atorvastatin. Furthermore, the medicine's solubility tests and dissolving rates in comparison to market and bulk drug Lipitor tablets were also looked at. Additionally, the research looked at the pharmacokinetics of solid dispersion and oral Lipitor delivery. Additionally, when comparing the oral ATC-P188 solid dispersion to that of Lipitor, the AUC0–8 h and Cmax increased. It can be shown from all of these that ATC-P188 solid dispersions are a potential way to increase ATC's oral bioavailability.